Frontier Pharma: Alzheimer’s Disease and Associated Indications – Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression | Frontier Pharma | Market Research Reports and Industry Analysis

Description

List of Tables

Table 1: Alzheimer’s Disease and Associated Indications, Global, Common Forms of Dementia, 2017 13

Table 2: Alzheimer’s Disease and Associated Indications, Global, Common Alzheimer’s Disease Symptoms by Disease Stage, 2017 14

Table 3: Alzheimer’s Disease and Associated Indications, Global, Scoring for Mini-Mental State Exam, 2017 15

Table 4: Alzheimer’s Disease and Associated Indications, Global, Scoring for the Alzheimer’s Disease Assessment Scale-Cognitive , 2017 16

Table 5: Alzheimer’s Disease and Associated Indications, Global, Common Physical and Psychological Symptoms Associated with Anxiety Disorders, 2017 26

Table 6: Alzheimer’s Disease and Associated Indications, Global, Common Forms of Depression, 2017 28

Table 7: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 64

Table 8: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting XXX, 2017 65

Table 9: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 66

Table 10: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting XXX, 2017 66

Table 11: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 68

Table 12: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting XXX, 2017 68

Table 13: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 69

Table 14: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting XXX, 2017 70

Table 15: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 71

Table 16: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting XXX, 2017 71

Table 17: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 72

Table 18: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting XXX, 2017 72

Table 19: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 73

Table 20: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting XXX, 2017 73

Table 21: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 74

Table 22: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting XXX, 2017 74

Table 23: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 75

Table 24: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting XXX, 2017 75

Table 25: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 76

Table 26: Alzheimer’s Disease and Associated Indications, Pipeline Programs Targeting XXX, 2017 76

Table 27: Alzheimer’s Disease and Associated Indications, Global, XXX, 2017 77

Table 28: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs XXX, 2017 78

Table 29: Alzheimer’s Disease and Associated Indications, Global, Key Features of XXX, 2017 79

Table 30: Alzheimer’s Disease and Associated Indications, Global, Pipeline Programs Targeting XXX, 2017 79

License Details

Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

Single User Licence

$6995

Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

Site Licence

$13990

Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

Global Licence

$20985

Order by Fax

Email to a colleague Enquire Before Buying

Prefer to speak to a team member? Call us on:

+44 161 359 5414

Or click here to contact us